control patients. Among patients with psychiatric disorders, CSF vasopressin was increased in manic patients, while in patients with depression CSFVconcentration of this hormone did not differ from that found in controls. However, an increase in CSF vasopressin level was found in patients recovering from a depression. The clinical significance of changes in CSF vasopressin concentrations in groups of patients with neurological and psychiatric disorders is still unknown.
The neurohypophyseal hormone arginine vasopressin (AVP) has been demonstrated in various extrahypothalamic locations within the central nervous sytem'-5 and AVP is found in the cerebrospinal fluid (CSF) of normally hydrated subjects in concentrations similar to or lower than the corresponding plasma concentrations.6-8 However, in a number of neurological disorders a diverging ratio of CSF/plasma concentration has been found indicating a separate regulation of the release of AVP into the CSF.9-" Several hypotheses on the function of AVP within the central nervous system have been offered. Vas- opressin in the CSF has been suggested to have an effect on brain water permeability'2 and on the intracranial pressure,'3 and a direct relationship between the intracranial pressure and CSF AVP concentration has been proposed." Several results from animal studies have suggested that AVP might influence leaming and memory functions, and low CSF concentrations of AVP have been found in patients with dementia.'617 Gold et fig. Mean CSF AVP concentration was 1-3 ± 0-1 pg/ml (SEM), and no difference was found between men (1-4 ± 0*1 pg/ml (SEM) and women (1-3 + 0-1 pg/ml (SEM). No statistical correlation was found between age and CSF AVP concentration (r = -0-01). Plasma AVP was higher than CSF AVP in all patients but three, but no statistical correlation was found between plasma and CSF vasopressin concentrations (r = 0-22; p > 0-1). Plasma and CSF osmolalities were Table 2 Vasopressin concentration and osmolality in CSF and plasma in groups ofpatients with different neurological disorders and in controls (Means + SEM). (1.4 + 0-1 pg/ml (SEM)) and ventricular (1-5 ± 0-1 pg/ml (SEM)) CSF from 17 patients with normal pressure hydrocephalus. Mean plasma AVP concentration was increased in patients with intracranial tumour and intracranial haemorrhage and decreased in patients with basal ganglia disorder and primary degenerative dementia when compared with mean plasma AVP in the control patients. No relationship was found between CSF and plasma AVP values in any of the patient groups, except in patients with benign intracranial hypertension (r = 0-65; p < 0-01).
Mean plasma and CSF osmolalities did not differ from the values found in controls except in the group of patients with cranio-cerebral trauma. Two patients with cranial trauma, two with intracranial tumour and one with subarachnoid haemorrhage had symptoms of inappropriate secretion of antidiuretic hormone syndrome with severe hypoosmolality (<260 mosm/kg) and hyponatraemia and normal or even high plasma AVP concentrations. The relationship between plasma osmolality and plasma AVP, which was demonstrated in the control patients, was not present in any group of patients with intracranial disorders, and several patients showed plasma AVP concentrations which in relation to the corresponding plasma osmolalities were outside the range found in normal subjects.24
Patients with psychiatric disorders CSF and plasma AVP concentrations and osmolalities are given in table 3 and fig. Mean CSF AVP concentration was higher in manic patients while depressive and schizophrenic patients had values similar to that found in control patients. However, in 12 endogenous depressive patients who were examined during depression and reexamined after recovery, CSF AVP was lower in the state of depression (1-2 + 0-1 pg/ml (SEM)) than after recovery (1.5 + 0-1 pg/ml (SEM); p < 0.05).
Mean plasma AVP was not different from that found in control patients in any group of psychiatric patients. In patients with endogenous depression and in patients with mania plasma AVP and CSF AVP concentrations were significantly correlated (r = 0-47 and r = 0*82, respectively; p < 0.01), whereas such a correlation was not seen in the control patients.
Plasma and CSF osmolalities were within the normal range (table 3) , but a relationship between plasma osmolality and plasma AVP, as found in the controls, could not be demonstrated in any group of psychiatric patients.
Discussion
The concentration of AVP in CSF was increased in those intracranial disorders that commonly cause raised intracranial pressure. This is consistent with previous findings of a direct relationship between the intracranial pressure and CSF AVP concentration in a smaller series of patients with intracranial The inability of AVP and synthetic analogues to pass the blood-CSF barrier04' might be the main cause for the negative results in trials using intranasally drug administration.
In the present study, the AVP concentration in CSF of endogenously depressed patients was not different from that found in controls, whereas CSF AVP was increased in manic patients. Thus, the result of the present study is not inconsistent with the findings of Gold et a14243 that CSF AVP is decreased in the depressed state of affective illness and increased in mania, as we observed an increase in CSF AVP concentration in patients who recovered from a depression. In a previous study we have shown that treatment of depressed patients with electroconvulsive therapy evokes a marked but transient increase in plasma AVP concentration, and a trend toward a moderate rise in basal plasma AVP levels was found in patients who responded satisfactorily to electroconvulsive therapy."
The present study has demonstrated that significant alterations in CSF AVP levels can be found in various neurological and psychiatric diseases. However, the clinical significance of changes in CSF AVP levels is still obscure and further studies are needed on this subject. This study was supported by grants from the Danish Medical Research Council.
